At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
SP16drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
SP16 Inflammatory Response Inhibition Trial
In Brief
A Phase 2 clinical trial evaluating SP16 for Myocardial Infarction and Inflammation. Completed, enrolled 10 participants across 1 site.
Detailed Summary
This study will evaluate the potential benefit of blocking inflammation during a heart attack using an investigational anti-inflammatory medicine called SP16. The study will enroll 10 patients and all 10 patients will receive a standard dose of SP16.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyocardial Infarction, Inflammation
CountriesUnited States
CollaboratorsVirginia Commonwealth University
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJan 2020
Enrollment StartFeb 2020
Primary CompletionJan 2021
Study CompletionDec 2021
TodayJul 2026
First PostedJan 13, 2020
Enrollment StartFeb 24, 2020
Primary CompletionJan 4, 2021
Study CompletionDec 21, 2021
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 6.5 years ago
Interventions
SP16drug
All patients will receive a single dose of SP16